Jazz’s collaboration with ImmunoGen

In August 2017, Jazz Pharmaceuticals (JAZZ) and ImmunoGen (IMGN) entered into a strategic collaboration and option agreement. The collaboration provides Jazz Pharmaceuticals exclusive worldwide rights to opt into the development and marketing of two early-stage, hematology-related ADC (antibody-drug conjugate) programs, and other future programs to be selected.

For programs that Jazz selects to opt into, ImmunoGen will receive milestone payments based on regulatory approvals of the appropriate products. ImmunoGen will also receive royalties as a percentage of market sales from Jazz.

Behind Jazz’s Strategic Collaboration with ImmunoGen

By the terms of the agreement, both Jazz and ImmunoGen is entitled to share the costs related to the development and obtaining regulatory approval for the products in the US and the European Union.

Collaboration programs

The collaboration includes IMGN779, an investigational CD33-targeted ADC for the treatment of AML (acute myeloid leukemia), which is currently in a phase-1 clinical trial, and IMGN632, an investigational CD123-targeted ADC for hematological malignancies, which is anticipated to enter clinical trials by the end of 2017.

Jazz will pay ImmunoGen an advance payment of $75 million, and another $100 million over the next seven years, as development funding to support three ADC programs.

Notably, the American Cancer Society estimated that in the US, ~21,380 new cases of acute myeloid leukemia could be diagnosed in 2017, with around 10,590 deaths. Another study estimated that ~85%–90% patients with AML are CD33-positive. (CD-33 positive refers to the presence of CD33 antigen on more than ~20% to 25% of blasts from the marrow.)

IMGN779 is a humanized anti-CD33 antibody and is expected to help manage AML patients. The collaboration is expected to strengthen Jazz’s oncology pipeline.

On September 1, 2017, the FDA (US Food and Drug Administration) approved Pfizer’s (PFE) Mylotarg for the treatment of individuals with AML who are CD33 positive.

In the leukemia drug market, Jazz will compete with AbbVie (ABBV), Amgen, Astellas Pharma, Astex Pharmaceuticals, Celgene, and Agios Pharmaceuticals (AGIO). Notably, the Vanguard Health Care ETF (VHT) has ~0.24% of its total portfolio holdings in Jazz Pharmaceuticals.

Latest articles

Today, Canopy Growth announced that it acquired the Saskatchewan-based KeyLeaf Life Sciences along with entities relating to the company and its intellectual property. Here's what you need to know about the completed deal.

Yesterday, Tyson Foods (TSN) and fellow meat producers Pilgrim’s Pride (PPC) and Sanderson Farms (SAFM) took a hit to their stocks after news came out about an investigation over price-fixing allegations.

On June 24, RH (RH) was trading at $115.01, implying a rise of 21.2% since its announcement of its first-quarter earnings results on June 12. Despite the surge in its stock price, the company is still trading at a discount of 29.1% to its 52-week high.

26 Jun

Roku Stock Fell Close to 7.0% Yesterday

WRITTEN BY Aditya Raghunath

Roku stock fell 6.8% yesterday to close trading at $93.25 per share. Roku stock has lost over 9.0% in market value in the last two trading days. Prior to this pullback, Roku stock was up a whopping 235.0% year-to-date.

26 Jun

Beyond Meat Stock Up Today on New Product Launch

WRITTEN BY Rajiv Nanjapla

Today, Beyond Meat (BYND) announced that its new product, Beyond Beef, will hit markets across the US later this week.

FedEx (FDX) ended fiscal 2019 on a dismal note and reported a significant YoY decline in fourth-quarter earnings. The delivery giant posted adjusted EPS of $5.01, which was 15.2% lower than the year-ago quarter’s earnings of $5.91. The company cited sluggish revenue growth and increased expenses as the main reason behind the dismal bottom-line performance.